3.85

0.52% 0.02

After Hours: 3.85

Arbutus Biopharma Corp (ABUS)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Arbutus Biopharma Corp stock is traded at $3.85, with a volume of 668.86K. It is up +0.52% in the last 24 hours and down -0.52% over the past month. Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.

Previous Close:

$3.83

Open:

$3.79

24h Volume:

668.86K

Relative Volume:

0.60

Market Cap:

$721.51M

Revenue:

$12.99M

Net Income/Loss:

$-74.39M

P/E Ratio:

-8.3696

EPS:

-0.46

Net Cash Flow:

$-78.92M

1W Performance:

-4.70%

1M Performance:

-0.52%

6M Performance:

+49.22%

1Y Performance:

+89.66%

1-Day Range:

$3.79

$3.90

1-Week Range:

$3.79

$4.06

52-Week Range:

$1.69

$4.725

Arbutus Biopharma Corp Stock (ABUS) Company Profile

Name

Arbutus Biopharma Corp

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

604-419-3200

Address

701 VETERANS CIRCLE, WARMINSTER, PA

Employee

Twitter

@arbutusbio

Next Earnings Date

2024-08-01

Latest SEC Filings

ABUS's Discussions on Twitter

Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-02-22	Upgrade	Jefferies	Hold → Buy
Feb-25-21	Initiated	Jefferies	Hold
Dec-17-20	Initiated	H.C. Wainwright	Buy
Jul-27-20	Resumed	JMP Securities	Mkt Outperform
Jul-24-20	Downgrade	Robert W. Baird	Outperform → Neutral
May-19-20	Upgrade	Wedbush	Neutral → Outperform
Mar-06-20	Upgrade	Chardan Capital Markets	Neutral → Buy
Feb-20-20	Initiated	Robert W. Baird	Outperform
Feb-05-20	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform
Oct-07-19	Reiterated	B. Riley FBR	Buy
Oct-04-19	Downgrade	Chardan Capital Markets	Buy → Neutral
Oct-16-18	Upgrade	B. Riley FBR	Neutral → Buy
Oct-15-18	Upgrade	Wedbush	Underperform → Neutral
Oct-12-18	Reiterated	Chardan Capital Markets	Buy
Jul-06-18	Downgrade	B. Riley FBR, Inc.	Buy → Neutral
Mar-19-18	Resumed	Chardan Capital Markets	Buy
Mar-19-18	Downgrade	Wedbush	Outperform → Neutral
Jan-05-18	Initiated	B. Riley FBR, Inc.	Buy
Apr-04-17	Upgrade	Chardan Capital Markets	Neutral → Buy
Feb-01-17	Reiterated	Wedbush	Outperform
Dec-13-16	Downgrade	Chardan Capital Markets	Buy → Neutral
Nov-30-16	Upgrade	Chardan Capital Markets	Neutral → Buy

View All

Arbutus Biopharma Corp Stock (ABUS) Latest News

Sep 29, 2024

Arbutus Biopharma Co. (NASDAQ:ABUS) Short Interest Up 8.3% in September - MarketBeat

Sep 29, 2024

Sep 27, 2024

Wall Street SWOT: Arbutus Biopharma stock navigates legal wins and pipeline focus - Investing.com

Sep 27, 2024

Arbutus Biopharma (NASDAQ:ABUS) Stock Price Down 2.8% - MarketBeat

Sep 27, 2024

Sep 26, 2024

Rhumbline Advisers Purchases 14,607 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

Sep 26, 2024

Sep 25, 2024

It would be worthwhile to take a closer look at Arbutus Biopharma Corp (ABUS) - US Post News

Sep 25, 2024

Has Arbutus Biopharma (ABUS) Outpaced Other Medical Stocks This Year? - Yahoo Finance

Sep 25, 2024

Sep 24, 2024

The growth track for Arbutus Biopharma Corp (ABUS) has changed recently - SETE News

Sep 24, 2024

Sep 23, 2024

Analyzing Ratios: Arbutus Biopharma Corp (ABUS)’s Financial Story Unveiled - The Dwinnex

Sep 23, 2024

Sep 21, 2024

Rubric Capital Management LP Invests $5.20 Million in Arbutus Biopharma Co. (NASDAQ:ABUS) - MarketBeat

Sep 21, 2024

Sep 20, 2024

ABUS (Arbutus Biopharma) Altman Z-Score : 0.43 (As of Sep. 20, 2024) - GuruFocus.com

Sep 20, 2024

Sep 19, 2024

Arbutus Biopharma Co. (NASDAQ:ABUS) Stock Position Lifted by Bank of New York Mellon Corp - Defense World

Sep 19, 2024

Sep 18, 2024